Zy Therapeutics is gearing up for an important presence at the 2025 American Epilepsy Society (AES) Annual Meeting, where the company will highlight meaningful progress on Kamini® (ZY-001)—its lead investigational therapy for Sturge-Weber syndrome (SWS)–related epilepsy and severe childhood-onset epilepsies.
During the meeting, the Zy team will present updates across several key areas that reflect the program’s advancing maturity:
- Scientific & Clinical Dossier Progress: New advancements in Kamini’s data package supporting its development pathway.
- Regulatory Planning: Preparations for upcoming FDA interactions aimed at shaping the next phase of development.
- TPP & Health Economics Refinements: Evolving thinking around the Target Product Profile and the potential economic impact for patients and healthcare systems.
- Phase 3 Trial Readiness: Clinical strategy updates designed to support Kamini’s progression toward late-stage clinical testing.
AES 2025 marks a critical milestone for Zy Therapeutics as the company advances toward delivering the first targeted therapeutic intervention designed specifically for SWS-related epilepsy. The team looks forward to engaging with clinicians, researchers, and the rare-disease community as this important program moves closer to its next chapter.
